• Cardiology-related adverse events of targeted therapies for CLL/SLL and MCL
  • Arthralgias/Myalgias Associated with Targeted Therapy for CLL/SLL/MCL
  • Multidisciplinary Perspectives on BTK Inhibitors Adverse Events Management in CLL and MCL
  • BTK inhibitors in CLL and MCL: Strategies for Managing Adverse Events

What's New

Newsletters
Cardiology-related adverse events of targeted therapies for CLL/SLL and MCL
Jeremy R. Stone, MD
CE Education
Acute Lymphoblastic Leukemia: Nursing Notes on Asparaginase Hypersensitivity and Silent Inactivation
Katelyn Oranges, MSN, CRNP, CPHON, and Joseph Sciasci, PharmD, BCOP
Newsletters
BTK inhibitors in CLL and MCL: Strategies for Managing Adverse Events
Julie M. Vose, MD, MB; Jeremy R. Stone, MD; Nicole Lamanna, MD; Peter Campbell, PharmD, BCOP
CE Education
Multidisciplinary Perspectives on BTK Inhibitors Adverse Events Management in CLL and MCL
Julie M. Vose, MD, MB – Chair; Jeremy R. Stone, MD; Nicole Lamanna, MD; Peter Campbell, PharmD, BCOP
Newsletters
Caring for Patients with CLL in Rural America
Satish Shanbhag, MD, MPH, FACP